-- Reported by Adam Feuerstein in Boston. Follow @AdamFeuerstein
TheStreet's biotech columnist offers his own report card on biotech stocks.
A look back at the year's worth of Adam Feuerstein's biotech tweets.
The imbalances in patient baseline characteristics provided an assist to Corbus' resunab treatment response and undermines the credibility of the trial results, a source says.
Celldex Therapeutics (CLDX) reported a narrower loss than analysts had anticipated for the 2016 second quarter after Monday's closing bell.
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a strong on high relative volume candidate